Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 17Leukemia, Myelomonocytic, Acute 11Leukemia, Monocytic, Acute 11Leukemia, Megakaryoblastic, Acute 11Leukemia, Erythroblastic, Acute 11Breast Neoplasms 11Congenital Abnormalities 9Leukemia 7Glioblastoma 7Recurrence 6Pancreatic Neoplasms 6Multiple Myeloma 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Eosinophilic, Acute 5Leukemia, Basophilic, Acute 5Gliosarcoma 5Carcinoma, Non-Small-Cell Lung 5Anemia, Refractory, with Excess of Blasts 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Breast Neoplasms, Male 4Brain Neoplasms 4Blast Crisis 4Urinary Bladder Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 3Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Neuroblastoma 3Melanoma 3

Interventions

Dexamethasone 111Cyclophosphamide 99Melphalan 91Bortezomib 69Peripheral Blood Stem Cell Transplantation 64Lenalidomide 58fludarabine phosphate 56Busulfan 54Filgrastim 50Tacrolimus 38Antilymphocyte Serum 38Thalidomide 36Radiotherapy 36Mycophenolic Acid 33fludarabine 28Cyclosporine 26Methotrexate 25Etoposide 22Calcium Dobesilate 22Whole-Body Irradiation 21Prednisone 21Methylprednisolone 20sargramostim 19pomalidomide 19Granulocyte Colony-Stimulating Factor 18carfilzomib 16daratumumab 15Cord Blood Stem Cell Transplantation 15Carmustine 14Rituximab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × tipifarnib × Clear all
NCT00005967 2013-02-11

Tipifarnib in Treating Patients With Advanced Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
36 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Pdgfra-Associated Chronic Eosinophilic Leukemia, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Primary Myelofibrosis

NCT00012350 2012-10-23

Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
44 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡